RT Journal Article
SR Electronic
T1 How Does Diabetes Affect Daily Life? A Beyond-A1C Perspective on Unmet Needs
JF Clinical Diabetes
JO diaclin
FD American Diabetes Association
SP 133
OP 137
DO 10.2337/cd17-0093
VO 36
IS 2
A1 Gopisetty, Divya
A1 Levine, Brian
A1 Liu, Nancy
A1 Younge, Phin
A1 Brown, Adam
A1 Close, Kelly L.
A1 Wood, Richard
YR 2018
UL http://clinical.diabetesjournals.org/content/36/2/133.abstract
AB IN BRIEF Given the progressive nature of type 2 diabetes, treatment intensification is usually necessary to maintain glycemic control. However, for a variety of reasons, treatment is often not intensified in a timely manner. The combined use of basal insulin and a glucagon-like peptide-1 receptor agonist is recognized to provide a complementary approach to the treatment of type 2 diabetes. This review evaluates the efficacy and safety of two co-formulation products, insulin degludec/liraglutide and insulin glargine/lixisenatide, for the treatment of type 2 diabetes inadequately controlled on either component agent alone. We consider the benefits and limitations of these medications based on data from randomized clinical trials and discuss how they may address barriers to treatment intensification.